SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2025-04-14 (juve-patent.com)
German Federal Patent Court upholds Xtandi patent in win for Astellas
Federal Patent Court upholds patent for prostate cancer drug in win for Xtandi Astellas and The Regents of the University of California.
Read more
2025-04-09 (cnmc.es)
He authorized eleven concentration operations in March |
All of them were approved in the first phase and without commitments. Several were starring companies dedicated to investment banking, funds from
Read more
2025-02-12 (businessupturn.com)
Zydus signs exclusive agreement with Synthon for a novel 505(B)(2) oncology product for US market |
Zydus Lifesciences Ltd., a leading global healthcare company, has signed an exclusive development, licensing, supply, and commercialization agreement with Synthon BV, Netherlands. This collaboration focuses on a novel 505(B)(2) oncology product for an undisclosed target, marking a significant advancement in cancer treatment. Under the agreement, Synthon will handle the development, manufacturing, and supply of the […]
Read more
2025-02-01 (doe.cl)
Santiago Court of Appeals rejected Synthon Chile claim and confirms partial delivery of clinical studies - | Legal News
The ISP ordered to targe any antecedent that says relationship or contains data that account for the formula of the products consulted, and of any personal data of context and sensitive data that they may contain.
Read more
2025-01-29 (juve-patent.com)
Another win for Astellas as Dutch court upholds Xtandi patent -
Astellas and Hoyng ROKH successfully defend formulation patent for Xtandi. The District Court The Hague dismissed Synthon's revocation claim.
Read more
2025-01-16 (mena.nl)
League Tables 2024: The final score for -law firms is known -
View the League Tables advertisement in the FD here. With 36 completed transactions and a total deal value of almost seventeen billion euros in 2024, De Brauw Blackstone Westbroek has had an impressive year. Some of the most high-profile deals the firm has worked on include the FrieslandCampina merger (deal value: 1.3 billion euros), the […]
Read more
2025-01-08 (expresspharma.in)
Deal value declined by 86.4 per cent in Dec 2024, compared to Dec 2023 -
Three major deals contributed 70 per cent of the total deal value during December 2024
Read more
2024-12-17 (investorsinhealthcare.com)
Netherlands: BC Partners sells stake in Synthon to Goldman Sachs Alternatives for reported US$2bn valuation - Investors in Healthcare
BC Partners sells stake in Synthon to Goldman Sachs Alternatives
Read more
2024-12-16 (citeline.com)
Goldman Sachs Takes Control Of Synthon
Synthon’s current owners, BC Partners, are selling a controlling stake in the Dutch complex generics specialist to Goldman Sachs Asset Management.
Read more
2024-11-01 (dailysabah.com)
EU slaps Israeli generic drugmaker Teva with $500M antitrust fine
The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on Israeli generic drugmaker Teva...
Read more
2024-10-31 (netnoticias.mx)
EU penalizes Teva for abuse of power, receives historic fine
500 million dollars for protecting patents and violating competition rules
Read more
2024-10-31 (lavoz.com.ar)
EU fines Teva 460 million euros for trying to protect patent for sclerosis medicine
EU fines Teva 460 million euros for trying to protect patent for sclerosis medicine
Read more